NIH Unperturbed by New Way of Peering into Personal Genomic Data
By Jocelyn Kaiser,
Science Insider
| 04. 10. 2012
In a provocative paper published this week, researchers say they have figured out a way to link a person's DNA to their anonymous genetic data in a certain kind of public research database. But the National Institutes of Health (NIH), which hosts one of the largest such databases, says it's not taking any new steps to prevent someone from using the method to breach privacy. That contrasts with NIH's response 4 years ago, when a similar study prompted the agency to pull genetic data from its public Web sites.
The issue then involved studies that compare DNA variants called single nucleotide polymorphisms (SNPs) in people with and without an illness to find disease risk markers. NIH had begun posting online pooled SNP results from hundreds of people, thinking privacy would not be breached. But then scientists reported in PloS Genetics that if they had a sample of an individual's DNA, they could link it to that person's SNP results within a public DNA pool. NIH (and the Wellcome Trust)
removed data from public sites; NIH now allows only approved...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...